Dr. Dan Peterson was at the epicenter of the Incline Village outbreak in the mid 1980’s that helped put CFS on the map. Stunned by the depth of the disorder Dr. Peterson has devoted most of his practice at Sierra Internal Medicine to treating chronic fatigue syndrome for the past three decades.
Dr. Peterson is a past board of directors and scientific advisory board member of the HHV-6 Foundation, a founding board member and past President of the IACFS/ME and a founding member of the Whittemore-Peterson-Institute in Reno, Nevada. Citing a lack of collaboration, Dr. Peterson left the Institute in March, 2010 at the height of the excitement over XMRV; his later study with Dr. Jay Levy suggested XMRV was a laboratory contaminant.
Dr. Peterson opened a new office in 2012 with a small laboratory. The head researcher for the Simmaron Foundation, Dr. Peterson is collaborating with the Chronic Fatigue Initiative and Ian Lipkin on its pathogen study, the Open Medicine Institute on a Rituximab trial, PHANU – the Australian ME/CFS research effort – on natural killer cell and spinal fluid studies, and the CDC in a multi-site diagnostics study. A list o.f his selected publications can be found on his Wikipedia page
Dr. Peterson received the Rudy Perpich award in 2003, and the Nelson Gantz Outstanding Clinician Award from the International Association for CFS/ME in 2007.
DR PETERSON ON PHOENIX RISING
- Looking Forward: Dr. Peterson on ME/CFS Research, Treatment Options and Hope for the Future (Oct 2011)
- Dr. Peterson Dr. Peterson Talks! On Ampligen, Autoimmunity, Pathogens and His New Partnership (July 2012)
Check out Corinne’s blogs as she relates her experiences seeing Dr. Peterson..
- Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Brenu EW, Ashton KJ, van Driel M, Staines DR, Peterson D, Atkinson GM, Marshall-Gradisnik SM.J Affect Disord. 2012 May 7. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
- Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.Brenu EW, van Driel ML, Staines DR, Ashton KJ, Hardcastle SL, Keane J, Tajouri L, PetersonD, Ramos SB, Marshall-Gradisnik SM. J Transl Med. 2012 May 9;10(1):88.
- A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, PetersonDL; Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM.PLoS One. 2012;7(3):e31334. Epub 2012 Mar 14.
- Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients withchronic fatigue syndrome. Silverman RH, Das Gupta J, Lombardi VC, Ruscetti FW, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Mikovits JA. Science. 2011 Oct 14;334(6053):176. No abstract available.
- Lombardi VC, Ruscetti FW, Das Gupta J, et al. (October 2009). “Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome”. Science 326 (5952): 585–9. Bibcode 2009Sci…326..585L. DOI:10.1126/science.1179052. PMID 19815723. (Retracted)
- Shetzline SE, Martinand-Mari C, Reichenbach NL, et al (April 2002). “Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome”. J. Interferon Cytokine Res. 22 (4): 443–56. DOI:10.1089/10799900252952235. PMID 12034027.
- Ablashi DV, Eastman HB, Owen CB, et al (May 2000). “Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients”. J. Clin. Virol. 16 (3): 179–91. DOI:10.1016/S1386-6532(99)00079-7. PMID 10738137.
- Suhadolnik RJ, Peterson DL, O’Brien K, et al (July 1997). “Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome”. J. Interferon Cytokine Res. 17 (7): 377–85. DOI:10.1089/jir.1997.17.377. PMID 9243369.
- Suhadolnik RJ, Reichenbach NL, Hitzges P, et al (1994). “Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome”. In Vivo 8 (4): 599–604. PMID 7893988.
- Suhadolnik RJ, Reichenbach NL, Hitzges P, et al (January 1994). “Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome”. Clin. Infect. Dis.. 18 Suppl 1: S96–104. PMID 8148461.
- Strayer DR, Carter WA, Brodsky I, et al (January 1994). “A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome”. Clin. Infect. Dis.. 18 Suppl 1: S88–95. PMID 8148460.
- Paul H. Levine, Daniel Peterson, Faye L. McNamee, Karen O’Brien, Gloria Gridley, Mary Hagerty, Jane Brady, Thomas Fears, Martin Atherton, and Robert Hoover (October 1992). “Does Chronic Fatigue Syndrome Predispose to Non-Hodgkin’s Lymphoma?”. Cancer Research (Suppl.) 52: 55l6s-55l8s.
- Daugherty SA, Henry BE, Peterson DL, Swarts RL, Bastien S, Thomas RS (1991). “Chronic fatigue syndrome in northern Nevada”. Rev. Infect. Dis.. 13Suppl 1: S39–44. PMID 1850542.
- Caligiuri M, Murray C, Buchwald D, et al (November 1987). “Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome”. J. Immunol. 139 (10): 3306–13. PMID 2824604.